Drug intelligence / Profile preview

armillarisin a

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Armillarisin A is a natural coumarin compound derived from traditional herbal remedies, notably from the plant Amomum villosum. It has demonstrated potential in modulating immune function, inhibiting bacterial growth, and regulating liver function. Armillarisin A increases IL-4 and lowers IL-1β, suggesting anti-inflammatory effects relevant to ulcerative colitis. It also impacts mitochondrial membrane potential and activates apoptotic pathways in cancer cells, indicating possible anticancer activity[1][2][4]. The drug is used as an effective cholagogue for cholecystitis and atrophic gastritis[9][10].

Brand names: Liangjunjiasu
Other names: ArmillarisinArmillarisinumARMILLARISIN A3-acetyl-5-hydroxymethyl-7-hydroxycoumarin3-acetyl-7-hydroxy-5-(hydroxymethyl)-2H-chromen-2-one

Targets

IL-4 (Interleukin 4)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on armillarisin a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on armillarisin a.

Explore the full profile